A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of Topical LFX453 Formulations in Patients With External Genital Warts (EGWs)
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs LFX 453 (Primary) ; Imiquimod
- Indications Genital warts
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 22 Aug 2016 Status changed from recruiting to completed.
- 03 Mar 2016 Planned End Date changed from 1 Jul 2016 to 1 May 2016 as per ClinicalTrials.gov record.
- 03 Mar 2016 Planned primary completion date changed from 1 Jul 2016 to 1 May 2016 as per ClinicalTrials.gov record.